T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cencora
COR
|
+$1.41B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$1.23B |
| 3 |
KKR & Co
KKR
|
+$1.06B |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$861M |
| 5 |
Broadcom
AVGO
|
+$822M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$1.18B |
| 2 |
HOLX
Hologic
HOLX
|
+$1.14B |
| 3 |
Cigna
CI
|
+$1.05B |
| 4 |
Roper Technologies
ROP
|
+$918M |
| 5 |
DTE Energy
DTE
|
+$834M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.82% |
| 2 | Healthcare | 20.04% |
| 3 | Consumer Discretionary | 13.58% |
| 4 | Financials | 12.54% |
| 5 | Industrials | 9.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Stanley Black & Decker
SWK
$15.5B
| – | – |
-66
| Closed | -$5K |
|
952
Teva Pharmaceuticals
TEVA
$42.8B
| – | – |
-1,468
| Closed | -$30K |
|
|
THS
953
DELISTED
Treehouse Foods
THS
| – | – |
-121
| Closed | -$3K |
|
954
TKO Group
TKO
$14.3B
| – | – |
-11
| Closed | -$3K |
|
955
Veracyte
VCYT
$3.59B
| – | – |
-450
| Closed | -$16K |
|
956
Watsco Inc
WSO
$12.8B
| – | – |
-42,586
| Closed | -$17.2M |
|
957
Watts Water Technologies
WTS
$12.9B
| – | – |
-22,970
| Closed | -$6.42M |
|
958
Dentsply Sirona
XRAY
$2.27B
| – | – |
-205
| Closed | -$3K |
|
|
ATYR
959
aTyr Pharma
ATYR
$53M
| – | – |
-141
| Closed | -$1K |
|
|
MTSR
960
DELISTED
Metsera Inc
MTSR
| – | – |
-2,327,354
| Closed | -$122M |
|
|
FLY
961
Firefly Aerospace
FLY
$4.44B
| – | – |
-1,407,595
| Closed | -$41.3M |
|
Similar funds
T. Rowe Price Investment Management's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Investment Management held 961 positions worth $158B, down 3.2% from $164B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
T. Rowe Price Investment Management withdrew a net $7.02B in Q4 2025, closing 63 positions and reducing 443 holdings. Its most notable exit was Bright Horizons, an estimated $240M position sold in full.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Investment Management opened a new position in Keurig Dr Pepper worth $728M.
- T. Rowe Price Investment Management's largest Q4 2025 buy was Keurig Dr Pepper: 25,978,817 shares worth $728M.
- T. Rowe Price Investment Management added most to Cencora in Q4 2025, an estimated $1.41B increase.
- T. Rowe Price Investment Management's biggest Q4 2025 reduction was Danaher, cutting an estimated $1.18B.
- T. Rowe Price Investment Management fully exited Bright Horizons in Q4 2025, selling an estimated $240M.
- T. Rowe Price Investment Management's ten largest holdings make up 23% of its $158B portfolio in Q4 2025.
- T. Rowe Price Investment Management opened 80 new positions and closed 63 in Q4 2025.
- T. Rowe Price Investment Management's portfolio value fell 3.2% quarter-over-quarter to $158B.
Based on T. Rowe Price Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.